WallStSmart

Boston Scientific Corp (BSX)vsWipro Limited ADR (WIT)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Wipro Limited ADR generates 4393% more annual revenue ($926.24B vs $20.61B). BSX leads profitability with a 17.3% profit margin vs 14.2%. BSX appears more attractively valued with a PEG of 0.68. BSX earns a higher WallStSmart Score of 71/100 (B).

BSX

Strong Buy

71

out of 100

Grade: B

Growth: 8.0Profit: 7.0Value: 5.3Quality: 5.5
Piotroski: 4/9

WIT

Buy

59

out of 100

Grade: C

Growth: 4.0Profit: 7.0Value: 6.3Quality: 6.8
Piotroski: 3/9Altman Z: 3.44
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BSXSignificantly Overvalued (-22.6%)

Margin of Safety

-22.6%

Fair Value

$46.16

Current Price

$53.93

$7.77 premium

UndervaluedFair: $46.16Overvalued

Intrinsic value data unavailable for WIT.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BSX4 strengths · Avg: 8.8/10
EPS GrowthGrowth
100.0%10/10

Earnings expanding 100.0% YoY

Market CapQuality
$84.08B9/10

Large-cap with strong market position

PEG RatioValuation
0.688/10

Growing faster than its price suggests

Operating MarginProfitability
20.6%8/10

Strong operational efficiency at 20.6%

WIT4 strengths · Avg: 9.0/10
Free Cash FlowQuality
$26.91B10/10

Generating 26.9B in free cash flow

Altman Z-ScoreHealth
3.4410/10

Safe zone — low bankruptcy risk

P/E RatioValuation
15.2x8/10

Attractively priced relative to earnings

Price/BookValuation
2.1x8/10

Reasonable price relative to book value

Areas to Watch

BSX0 concerns · Avg: 0/10

No major concerns identified

WIT2 concerns · Avg: 2.5/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

EPS GrowthGrowth
-1.6%2/10

Earnings declined 1.6%

Comparative Analysis Report

WallStSmart Research

Bull Case : BSX

The strongest argument for BSX centers on EPS Growth, Market Cap, PEG Ratio. Profitability is solid with margins at 17.3% and operating margin at 20.6%. Revenue growth of 11.6% demonstrates continued momentum.

Bull Case : WIT

The strongest argument for WIT centers on Free Cash Flow, Altman Z-Score, P/E Ratio. PEG of 1.29 suggests the stock is reasonably priced for its growth.

Bear Case : BSX

No major red flags identified for BSX, but monitor valuation.

Bear Case : WIT

The primary concerns for WIT are Piotroski F-Score, EPS Growth.

Key Dynamics to Monitor

BSX profiles as a mature stock while WIT is a value play — different risk/reward profiles.

BSX carries more volatility with a beta of 0.62 — expect wider price swings.

BSX is growing revenue faster at 11.6% — sustainability is the question.

WIT generates stronger free cash flow (26.9B), providing more financial flexibility.

Bottom Line

BSX scores higher overall (71/100 vs 59/100), backed by strong 17.3% margins and 11.6% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Boston Scientific Corp

HEALTHCARE · MEDICAL DEVICES · USA

Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.

Wipro Limited ADR

TECHNOLOGY · INFORMATION TECHNOLOGY SERVICES · USA

Wipro Limited is a global information technology (IT), consulting and business process services company. The company is headquartered in Bengaluru, India.

Want to dig deeper into these stocks?